MOBIDIAG-LTD.
9.10.2019 08:02:12 CEST | Business Wire | Press release
Mobidiag Ltd., a revenue generating, molecular diagnostics company with complementary platforms that address antimicrobial resistance and other areas of unmet diagnostic need, today announces the CE-IVD marking of the Novodiag® Stool Parasites test, a comprehensive and cost-effective molecular diagnostic test for the detection of intestinal parasites directly from stool samples.
Tuomas Tenkanen, CEO of Mobidiag, said, “Parasitic diseases contribute significantly to the burden of infectious diseases worldwide and current diagnostic methods such as microscopy are labor-intensive and require a high level of skill. Our Novodiag® Stool Parasites test is the only fully automated, rapid, cost-effective and easy to use diagnostic solution that can identify a comprehensive range of parasitic targets, for use in laboratories and hospitals.”
“Novodiag® Stool Parasites is the fourth test on our Novodiag® platform and, together with our Novodiag® C. difficile , Novodiag® Bacterial GE+ and Novodiag® CarbaR+ tests, further strengthens our offering in the detection of gastrointestinal infections. With our complementary Amplidiag® and Novodiag® solutions, we continue to offer a range of highly versatile combined solutions enabling the broad application of molecular diagnostics around the world.”
Novodiag® Stool Parasites combines real-time PCR and microarray technologies to allow cost-effective, rapid and comprehensive detection of >95% of intestinal parasites. This syndromic test is designed to run on-demand using the automated Novodiag® system and is able to detect the presence of nucleic acid markers corresponding to the identification of the most common protozoan, helminths, and microsporidia from stool samples. The test provides complete results in 90 minutes with less than five minutes hands-on time by an operator.
While most infections and death from parasitic diseases affect people in developing countries, increasing incidence in developed nations combined with a shortage of microscopy trained hospital staff are driving demand for this test.
The Novodiag® Stool Parasites test is now available directly through Mobidiag and local distributors. For more information, visit https://mobidiag.com/products/novodiag/#stoolparasites
About Novodiag®
Stool Parasites
Novodiag®
Stool Parasites is an automated qualitative nucleic acid-based diagnostic test for detecting the presence of nucleic acid markers corresponding to the identification of the most common protozoan, helminths, and microsporidia from stool samples. It is part of the Novodiag®
platform, Mobidiag’s fully automated molecular testing platform for diagnostics of infectious diseases and antibiotic resistances. Combining real-time PCR and microarray technologies, Novodiag®
platform allows direct analysis of a patient sample placed in a disposable cartridge for comprehensive screening of multiple or single pathogens. In addition of Novodiag®
C. difficile
, Novodiag®
Bacterial GE+ and Novodiag®
CarbaR+, we launch a new test, the Novodiag®
Stool Parasites which complements our offer for gastrointestinal infections. Our panel covers >95% of stool parasites.
About Mobidiag Ltd.
Mobidiag is a revenue generating, fast growing molecular diagnostics company with complementary platform technologies that can meet the differing diagnostic needs for customers in multiple healthcare settings. Initially designed for ease of use and adaptability for large scale manufacturing, Mobidiag’s Amplidiag®
and Novodiag®
platforms provide a combination of high quality and affordability, allowing for widespread applicability for both mass screening and highly specific syndromic testing in multiple indications. The Company’s highly versatile product offering enables the broad application of molecular diagnostics to address the global challenge of antimicrobial resistance and other unmet diagnostic needs. Mobidiag’s intial focus has been on gastrointestinal diseases and superbugs, through direct sales and distributors, and is rapidly building a leading position in European markets.
Mobidiag has more than 100 staff and is headquartered in Espoo, Finland, with subsidiaries in France, UK and Sweden. To learn more, visit www.mobidiag.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20191008005570/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Current Chemicals Expands U.S. Production of Rare-Earth Fluorides With New Investment From Momentum Global Ventures5.11.2026 14:14:00 CET | Press release
Current Chemicals receives additional capital to scale U.S. capacity for critical rare-earth fluorides used in magnets, advanced coatings, and alloys Current Chemicals, Inc. (“CCI”), one of the few U.S. companies converting separated rare-earth oxides into the fluorides used to make rare-earth metals and magnets, today announced an additional investment from its lead shareholder, Momentum Global Ventures (“MGV”). The investment will significantly increase CCI’s production of neodymium fluoride, dysprosium fluoride, and other key rare-earth fluorides in Cleveland. The funding adds infrastructure, equipment and engineering staff for fluorides of neodymium, dysprosium, terbium, gadolinium, yttrium, scandium, lanthanum, and lithium for reducing light rare-earths to metal: key inputs for permanent magnets, advanced coatings, and alloys. Neodymium fluoride and dysprosium fluoride are key feedstocks for the metal at the core of high-performance magnets in electric motors, wind turbines and de
iConnections and Preqin, a Part of BlackRock, Announce Collaboration to Bring Institutional Data to Violet, an AI-Powered Capital Introduction Platform5.11.2026 14:00:00 CET | Press release
Preqin's private markets data will be available inside Violet, iConnections' AI-powered capital introduction platform, to help drive networking and greater discovery for attendees of iConnections' Global Alts events iConnections today announced a collaboration with Preqin, a part of BlackRock, that brings one of the industry's leading sources of private markets data and intelligence— spanning fund managers, institutional investors, funds, benchmarks and indices— to Violet, iConnections' AI-powered capital introduction platform. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261105840622/en/ Preqin's data is now inside Violet Powered by Preqin, the integration gives Global Alts attendees access to a broader network of institutional alternatives market participants, inside the same platform where thousands of allocators and managers already discover one another, book meetings and build relationships. “Alternative investing has
SLB OneSubsea Awarded Contract for Lyra Field Development Offshore Norway5.11.2026 13:49:00 CET | Press release
Close collaboration and standardized subsea technology accelerate path to first production Global energy technology company SLB (NYSE: SLB) today announced that its OneSubsea™ joint venture has been awarded a contract by Aker BP to deliver subsea production systems, umbilicals and associated services for the Lyra field development, formerly known as Kjøttkake, on the Norwegian Continental Shelf (NCS). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104799196/en/ The SLB (NYSE: SLB) OneSubsea™ joint venture has been awarded a contract by Aker BP to deliver subsea production systems, umbilicals and associated services for the Lyra field development, formerly known as Kjøttkake, on the Norwegian Continental Shelf (NCS). Building on nearly a decade of collaboration through Aker BP’s alliance model, Aker BP and SLB OneSubsea worked together from the early stages of the project to shape the development strategy for Lyra. The fie
EURONAVAL 2026: Naval Group and Technology Innovation Institute (TII) Sign an Agreement to Pool Their Expertise in Advanced Autonomous Underwater Technologies.5.11.2026 12:48:00 CET | Press release
Signed on 3rd November 2026, the agreement brings together TII’s expertise in autonomous systems and Naval Group’s expertise in naval autonomous systems design, development and integration to explore the development and commercialization of advanced autonomous underwater solutions. The Technology Innovation Institute, the applied-research pillar of Abu Dhabi’s Advanced Technology Research Council (ATRC), has signed an agreement with Naval Group, a global leader in naval defense, to advance cooperation in autonomous underwater technologies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261105684133/en/ EURONAVAL 2026: Naval Group and Technology Innovation Institute (TII) sign an agreement to pool their expertise in advanced autonomous underwater technologies. (Photo: AETOSWire) Announced during Euronaval 2026, the collaboration will focus on exploring opportunities for the joint development and commercialization of uncrewed
BeOne Medicines Announces Third Quarter 2026 Financial Results and Business Updates5.11.2026 12:00:00 CET | Press release
Total global revenues of $1.9 billion for the third quarter, an increase of 34% from the prior yearBRUKINSA (zanubrutinib) global revenues of $1.4 billion for the third quarter, an increase of 34% from the prior yearDiluted GAAP Earnings per American Depository Share (ADS) of $3.28 for the third quarter; non-GAAP diluted Earnings per ADS of $4.59 for the third quarterRaised 2026 total revenue guidance to $6.9 to $7.0 billion; GAAP operating income of $1.2 to $1.3 billion, non-GAAP operating income of $1.9 to $2.0 billion BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced financial results and corporate updates from the third quarter of 2026. John V. Oyler, Co-Founder, Chairman, and CEO, BeOne, said: “Our strong third quarter results and raised full-year guidance reflect continued rapid global growth and leadership in hematology, anchored by our foundational BTK inhibitor BRUKINSA, which drives powerful and sustained responses in pat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom